Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Oxaliplatin, and Bevacizumab in First-Line NSCLC
NCT00356122Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jul 2006; status: completed.
02
Drugs
docetaxeloxaliplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00356122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356122.